{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-007139","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.801354+00:00","generated_at":"2026-06-18T07:34:19.396110+00:00","sec_items":["2.02","5.03","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Foghorn reports FY2022 net loss $108.9M; cash $345.8M; pipeline data expected H1 2023","bullets":["Net loss $108.9M for FY2022; R&D expenses $105.6M, collaboration revenue $19.2M.","Cash, equivalents and marketable securities $345.8M as of Dec 31, 2022; runway into H2 2025.","Phase 1 data for FHD-286 in mUM expected H1 2023; AML/MDS clinical hold update H1 2023.","Phase 1 data for FHD-609 in synovial sarcoma expected mid-2023.","Newly disclosed selective EP300 degrader targeting CBP mutant cancers; potential for >100K patients/year."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-007139","json":"https://secwatch.observer/filing/0001628280-23-007139.json","markdown":"https://secwatch.observer/filing/0001628280-23-007139.md","text":"https://secwatch.observer/filing/0001628280-23-007139.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828023007139/0001628280-23-007139-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828023007139/fhtx-20230307.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T07:34:19.396110+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6e2c87ed7bdb311b7b89700e318b888a156d86cd","claim":"Foghorn Therapeutics Inc.: Amended and restated bylaws to address universal proxy rules under Rule 14a-19 (effective 2023-03-07).","evidence_excerpt":"On March 7, 2023, in connection with the effectiveness of new Securities and Exchange Commission rules regarding universal proxy cards and a periodic review of the Company's bylaws, the Company's board of directors approved and adopted amended and restated bylaws (the “Amended and Restated Bylaws”), which became immediately effective.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828023007139/0001628280-23-007139-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-03-07"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}